Drug & Supplement Interactions

Transfer Factor + Ipilimumab

Brand name of Ipilimumab

  • Yervoy

Medically reviewed by

Also reviewed by the HelloPharmacist Editorial Team

Updated July 2026Details about this page

AI is used only to summarize verified clinical information, never the open internet. Our AI policy

The Bottom Line No Known Interaction

We found no known interaction between Transfer Factor and Ipilimumab in our sources.

This also applies to Yervoy, a brand name of ipilimumab.

Still Worth Knowing

  • Shared side effects: Although there is no interaction, both can cause some of the same side effects. Taken together, those side effects might add up, and a new symptom can be harder to pin on one or the other.
See the Full Interaction Report

Ask a Question About This Combination

Ask in your own words about taking Transfer Factor with Ipilimumab. The answer comes from this page’s own records.

Try:

AI answers from this page’s interaction records and our own drug and supplement information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist. How we use AI

Interaction Report

Transfer Factor and Ipilimumab Interaction Check

No Known Interaction Found

We did not find a documented interaction between Ipilimumab and Transfer Factor in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

How We Checked

Why No Interaction Is Listed for Ipilimumab

Neither one has a record. Our interaction database holds no record for Transfer Factor with any drug, and none for Ipilimumab with any supplement, so this rests on missing data, not on a study that found nothing.

Still wondering about combining Transfer Factor and Ipilimumab? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Know someone taking this combination? Share

Before You Combine Them

Taking Transfer Factor and Ipilimumab Together

What to Watch For

Side Effects Transfer Factor and Ipilimumab Have in Common

5 side effects show up for both Transfer Factor and Ipilimumab.

  • Each has separately been linked to the effects below. Taken together, they might add up: the same side effect from two sources might be more likely or stronger. No study of the two together says by how much.
  • If one turns up, it can be harder to tell which one is behind it, so tell your pharmacist you take both.
  • Acne Additional detail

    Transfer Factor

    Orally or parenterally, transfer factor seems to be well tolerated. Adverse effects may include fever. Parenterally, transfer factor can cause nausea, fatigue, and tenderness, pain, and swelling at the injection site.

    Source: , the clinical database we license.

    6 references cited
    1. 350. Jones JF, Minnich LL, Jeter WS, et al. Treatment of childhood combined Epstein-Barr virus/cytomegalovirus infection with oral bovine transfer factor. Lancet 1981;2:122-4. PubMed
    2. 1445. Louie E, Borkowsky W, Klesius PH, et al. Treatment of cryptosporidiosis with oral bovine transfer factor. Clin Immunol Immunopathol 1987;44:329-34. PubMed
    3. 1507. Fudenberg HH. Transfer factor: past, present and future. Annu Rev Pharmacol Toxicol 1989;29:475-516. PubMed
    4. 3062. Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988;61:1543-9. PubMed
    5. 3063. Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in Stage II malignant melanoma. Cancer 1983;51:269-72. PubMed
    6. 7562. Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203. PubMed

    Orally, transfer factor may cause severe acne in some patients.

    Source: , the clinical database we license.

    1 reference cited
    1. 78820. De Vinci, C., Levine, P. H., Pizza, G., Fudenberg, H. H., Orens, P., Pearson, G., and Viza, D. Lessons from a pilot study of transfer factor in chronic fatigue syndrome. Biotherapy 1996;9(1-3):87-90. PubMed

    Ipilimumab

    Source: Ipilimumab’s

    It lists this side effect in its Adverse Reactions section.

    Read Ipilimumab’s label on DailyMed ›
  • Fever reported in 4.8% of FDA reports for Ipilimumab Additional detail

    Transfer Factor

    Orally or parenterally, transfer factor may cause fever.

    There is some concern that bovine-derived transfer factor that is produced from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be contaminated with diseased tissue. Countries where BSE has been reported include Great Britain, France, the Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium.

    Source: , the clinical database we license.

    4 references cited
    1. 1507. Fudenberg HH. Transfer factor: past, present and future. Annu Rev Pharmacol Toxicol 1989;29:475-516. PubMed
    2. 78789. Thestrup-Pedersen, K., Grunnet, E., and Zachariae, H. Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Derm.Venereol. 1982;62(1):47-53. DOI
    3. 78809. Fernandez, O., Diaz, N., Morales, E., Toledo, J., Hernandez, E., Rojas, S., Madriz, X., and Lopez, Saura P. Effect of transfer factor on myelosuppression and related morbidity induced by chemotherapy in acute leukaemias. Br.J.Haematol. 1993;84(3):423-427 PubMed
    4. 1825. Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.

    Ipilimumab

    Source: Ipilimumab’s

    It lists this side effect in its Adverse Reactions section. Voluntary reports to the FDA mention it too.

    Read Ipilimumab’s label on DailyMed ›
  • Tiredness reported in 3.9% of FDA reports for Ipilimumab Additional detail

    Transfer Factor

    Parenterally, fatigue has been reported for up to 4 hours in a patient using transfer factor.

    Source: , the clinical database we license.

    1 reference cited
    1. 78789. Thestrup-Pedersen, K., Grunnet, E., and Zachariae, H. Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Derm.Venereol. 1982;62(1):47-53. DOI

    Ipilimumab

    Source: Ipilimumab’s

    It lists this side effect in its Adverse Reactions section. Voluntary reports to the FDA mention it too.

    Read Ipilimumab’s label on DailyMed ›
  • Swelling Additional detail

    Transfer Factor

    Parenterally, transfer factor may cause tenderness, pain, and swelling at the injection site.

    Source: , the clinical database we license.

    4 references cited
    1. 3062. Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988;61:1543-9. PubMed
    2. 7562. Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203. PubMed
    3. 7799. Fog T, Pedersen L, Raun NE, et al. Long-term transfer-factor treatment for multiple sclerosis. Lancet 1978;1:851-3. PubMed
    4. 78809. Fernandez, O., Diaz, N., Morales, E., Toledo, J., Hernandez, E., Rojas, S., Madriz, X., and Lopez, Saura P. Effect of transfer factor on myelosuppression and related morbidity induced by chemotherapy in acute leukaemias. Br.J.Haematol. 1993;84(3):423-427 PubMed

    Ipilimumab

    Source: Ipilimumab’s

    It lists this side effect in its Adverse Reactions section.

    Read Ipilimumab’s label on DailyMed ›
  • Nausea Additional detail

    Transfer Factor

    Parenterally, nausea has been reported in a patient following treatment with transfer factor

    Source: , the clinical database we license.

    1 reference cited
    1. 78809. Fernandez, O., Diaz, N., Morales, E., Toledo, J., Hernandez, E., Rojas, S., Madriz, X., and Lopez, Saura P. Effect of transfer factor on myelosuppression and related morbidity induced by chemotherapy in acute leukaemias. Br.J.Haematol. 1993;84(3):423-427 PubMed

    Ipilimumab

    Source: Ipilimumab’s

    It lists this side effect in its Adverse Reactions section.

    Read Ipilimumab’s label on DailyMed ›

Note: Effects for Ipilimumab come from the Adverse Reactions section of its FDA label; effects for Transfer Factor come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 42,912 voluntary FDA FAERS reports for Ipilimumab that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. The two sources word some effects differently, so we match them by meaning.

If You Decide to Take Both
  • Add one new thing at a time, and note the date you started it.
  • A start date turns “I’ve been feeling off” into something a pharmacist can work with.
  • Do not stop a prescribed medicine on your own.
  • Check with your pharmacist or doctor before changing any medicine or supplement, especially if you take several or have an ongoing health condition.
Overlapping Uses

Using Transfer Factor for the Same Condition as Ipilimumab

Why This Matters

  • The same goal. Ipilimumab is prescribed for melanoma and lung cancer, and Transfer Factor has been studied for them too.
  • It might help, or it might go too far. If Transfer Factor does work for them, the two effects might add up. That might mean better control, or it might go further than intended.
  • Tell your prescriber. A graded use is not a treatment, so do not stop or replace Ipilimumab on your own. If you take Transfer Factor for the same reason, your prescriber may want to keep a closer eye on how Ipilimumab is working.

Ipilimumab is a prescription medicine with approved uses on its FDA label. Transfer Factor is a supplement: here is what researchers have looked at it for, and how strong that evidence is.

From the FDA Label

Ipilimumab Is Prescribed For

Yervoy (ipilimumab) treats several cancers. Most uses are in combination with another immunotherapy medicine, nivolumab.

Read the rest of what Ipilimumab is prescribed for

It is used for melanoma (alone or with nivolumab), and after surgery for certain melanoma. It is also used with nivolumab for renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma and esophageal squamous cell carcinoma. Each use has specific criteria, such as tumor testing or prior treatment.

From the Natural Medicines Research Record

Transfer Factor Has Been Studied For

  • Melanoma Studied, Not Established
    Read what the research shows

    Administering human-derived transfer factor intramuscularly or subcutaneously, as adjuvant therapy, does not seem to affect disease progression or prolong survival when used for up to 2 years following surgery for Stage I and Stage II melanoma.

    3 references cited
    1. 3062. Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988;61:1543-9. PubMed
    2. 3063. Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in Stage II malignant melanoma. Cancer 1983;51:269-72. PubMed
    3. 78691. Miller, L. L., Spitler, L. E., Allen, R. E., and Minor, D. R. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 4-15-1988;61(8):1543-1549. PubMed
  • Lung cancer Studied, Not Established
    Read what the research shows

    Most research shows that administering human-derived transfer factor intramuscularly or subcutaneously, in combination with lung resection and chemotherapy, does not increase survival in patients with lung cancer. However, some preliminary evidence suggests that transfer factor might improve survival in lung cancer patients with Stage IIIA or IIIB disease.

    4 references cited
    1. 5447. Whyte RI, Schork MA, Sloan H, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992;53:391-6. PubMed
    2. 7800. Fujisawa T, Yamaguchi Y, Kimura H, et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984;54:663-9. PubMed
    3. 78793. Fujisawa, T., Yamaguchi, Y., Kimura, H., Arita, M., Shiba, M., and Baba, M. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn.J.Surg. 1984;14(6):452-458. PubMed
    4. 78824. Pilotti, V., Mastrorilli, M., Pizza, G., De, Vinci C., Busutti, L., Palareti, A., Gozzetti, G., and Cavallari, A. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996;9(1-3):117-121. PubMed

The grades and the research summaries are from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”.

Get to Know Each One

About Transfer Factor and Ipilimumab

Supplement

About Transfer Factor

Transfer factors are small immune molecules taken from cow colostrum or egg yolk and sold as supplements meant to boost or 'train' the immune system. Solid human evidence for the supplement products is limited, and quality varies widely between brands. Talk with your pharmacist or doctor before using one, especially if you have an immune condition.

Full Transfer Factor guide: uses, dosage, safety and every interaction
Safety at a Glance

How Transfer Factor Is Rated

  • Transfer Factor Overall

    Use caution

    Generally well tolerated in studies, but long-term safety and product quality are not well established.

  • Pregnancy

    Avoid

    Safety has not been established, so it is best avoided during pregnancy.

  • Breastfeeding

    Avoid

    Not enough safety information exists, so avoid while breastfeeding.

Medication

About Ipilimumab Injection

More to Explore

More Pairs and Interactions to Check

Keep Checking

Other Drugs & Transfer Factor

Browse every other medication we’ve checked against Transfer Factor — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
No Interaction 2,829 drugs checked — show the list
How Much People Look This Up

Where Transfer Factor and Ipilimumab Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Transfer Factor
Top half

#683 of 1,458 supplements looked up here in the last 7 days

29 days ago today
Medication Ipilimumab
Steady interest

#2,089 of 2,830 medications looked up here in the last 7 days

29 days ago today

A rank of lookups on this site, not of how often either one is used. It counts every visit, automated ones included, and identifies no one.

Questions and Sources

Common Questions and Where This Comes From

Pharmacist Counseling Corner

Taking Transfer Factor and Ipilimumab Together: Common Questions

Can you take Transfer Factor with Ipilimumab?
We do not list a known interaction between Transfer Factor and Ipilimumab. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Can you take Transfer Factor with Yervoy?
Yervoy is a brand name of ipilimumab, so the answer is the same as for ipilimumab. We do not list a known interaction between Transfer Factor and Ipilimumab. Everything on this page applies to Yervoy too.
Do Transfer Factor and Ipilimumab have any of the same side effects?
Yes — our sources link each of them separately to 5 of the same effects. That is not a documented interaction, but taken together the same side effect from two sources might be more likely or stronger; no study of the two together says by how much. And if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Are Transfer Factor and Ipilimumab used for the same thing?
They overlap in purpose, which usually means the real question is whether you need both rather than whether they are safe together. This page lists the shared uses and how strong the evidence is for Transfer Factor in each. That is a conversation for your prescriber, especially if Ipilimumab is being adjusted to a target.

Written and reviewed by the HelloPharmacist Editorial Team. Our editorial policy

Evidence & Sources

References Cited on This Page

The 16 references the cards above cite, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Show the 16 references
  1. 350. Jones JF, Minnich LL, Jeter WS, et al. Treatment of childhood combined Epstein-Barr virus/cytomegalovirus infection with oral bovine transfer factor. Lancet 1981;2:122-4. PubMed
  2. 1445. Louie E, Borkowsky W, Klesius PH, et al. Treatment of cryptosporidiosis with oral bovine transfer factor. Clin Immunol Immunopathol 1987;44:329-34. PubMed
  3. 1507. Fudenberg HH. Transfer factor: past, present and future. Annu Rev Pharmacol Toxicol 1989;29:475-516. PubMed
  4. 1825. Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.
  5. 3062. Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988;61:1543-9. PubMed
  6. 3063. Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in Stage II malignant melanoma. Cancer 1983;51:269-72. PubMed
  7. 5447. Whyte RI, Schork MA, Sloan H, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992;53:391-6. PubMed
  8. 7562. Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203. PubMed
  9. 7799. Fog T, Pedersen L, Raun NE, et al. Long-term transfer-factor treatment for multiple sclerosis. Lancet 1978;1:851-3. PubMed
  10. 7800. Fujisawa T, Yamaguchi Y, Kimura H, et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984;54:663-9. PubMed
  11. 78691. Miller, L. L., Spitler, L. E., Allen, R. E., and Minor, D. R. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 4-15-1988;61(8):1543-1549. PubMed
  12. 78789. Thestrup-Pedersen, K., Grunnet, E., and Zachariae, H. Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Derm.Venereol. 1982;62(1):47-53. DOI
  13. 78793. Fujisawa, T., Yamaguchi, Y., Kimura, H., Arita, M., Shiba, M., and Baba, M. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn.J.Surg. 1984;14(6):452-458. PubMed
  14. 78809. Fernandez, O., Diaz, N., Morales, E., Toledo, J., Hernandez, E., Rojas, S., Madriz, X., and Lopez, Saura P. Effect of transfer factor on myelosuppression and related morbidity induced by chemotherapy in acute leukaemias. Br.J.Haematol. 1993;84(3):423-427 PubMed
  15. 78820. De Vinci, C., Levine, P. H., Pizza, G., Fudenberg, H. H., Orens, P., Pearson, G., and Viza, D. Lessons from a pilot study of transfer factor in chronic fatigue syndrome. Biotherapy 1996;9(1-3):87-90. PubMed
  16. 78824. Pilotti, V., Mastrorilli, M., Pizza, G., De, Vinci C., Busutti, L., Palareti, A., Gozzetti, G., and Cavallari, A. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996;9(1-3):117-121. PubMed

All 49 references behind our Transfer Factor records are listed in the Transfer Factor guide.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is reviewed by the HelloPharmacist Editorial Team. See our data sources and editorial standards.

Where Does Our Data Come From?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 105,612 references behind our interaction content, 67,053 of them resolved to verified PubMed/DOI sources. See the references behind this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified November 22, 2026. The Transfer Factor and Ipilimumab records this page draws on were last updated July 10, 2026.
Data structure & sourcing designed and verified by .
Rating Key

What Our Interaction Ratings Mean

No interaction is on record for this pair. The other supplements and medicines on this page carry a severity rating: how serious an interaction between them is.

See what each severity means

Severity: How Serious Is It?

How clinically significant the interaction is: how much it could affect your health or your treatment.

  • MajorClinically significant. Best to avoid the combination, or use only under close professional supervision.
  • ModerateBe cautious. The combination may call for monitoring, timing changes, or a dose adjustment.
  • MinorLimited clinical concern, but still worth being aware of and mentioning to your pharmacist.
  • No Known InteractionNo documented interaction in our sources.

Still Have a Question About Transfer Factor and Ipilimumab?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.